# A tumour result does not automatically describe inherited DNA

Draft • Research checked 4 October 2026 • AI-assisted DomDNA editorial content. No independent clinical review or publication is claimed. General education, not individual medical advice.

The words “genetic testing” can refer to different questions in cancer care. One test may examine changes in tumour cells to help characterise the cancer. Another may investigate an inherited predisposition that could matter to the person and their relatives. The overlap in gene names can hide the difference.

Before reading a result as a family finding, identify the purpose of the test and the material examined. A gene name alone does not tell you whether a change arose in the tumour or was present constitutionally.

## Two purposes, sometimes overlapping findings

The [NCI biomarker-testing explanation](https://www.cancer.gov/about-cancer/treatment/types/biomarker-testing-cancer-treatment) describes tumour testing as a way to examine biomarkers that may inform cancer treatment. Such testing can sometimes suggest an inherited change, but another test may be needed to establish that.

The [NHS explanation of constitutional and somatic variants](https://www.genomicseducation.hee.nhs.uk/genotes/knowledge-hub/constitutional-germline-vs-somatic-tumour-variants/) distinguishes changes present constitutionally from changes arising in tumour cells. The distinction concerns biological context, not whether a result is more or less serious.

An inherited-risk assessment and a tumour analysis can therefore use the same familiar gene while providing different information. You cannot replace the purpose statement with a generic label such as “DNA result”.

## A hypothetical report handover

Imagine someone receives a tumour report and sends a relative a screenshot naming a gene. The relative interprets it as proof that everyone in the family needs the same test. This is a hypothetical communication example, not a clinical case.

The screenshot has omitted the report type, specimen and interpretation. Restoring those details changes the conversation. The question becomes whether the finding suggests a constitutional change and whether the clinical team recommends a separate inherited-risk assessment.

A better private message would say that a tumour result has raised a question about possible inherited relevance and that the person is seeking clarification. That preserves uncertainty without withholding the existence of the question.

It would be equally unhelpful to assume that every tumour finding is definitely unrelated to inheritance. The correct distinction is that the tumour result alone may not settle the inherited question.

## Blood is not a complete purpose label

A sample described as blood can be used for different analyses. For example, cancer-related testing can involve tumour material or tumour-derived signals, while constitutional assessment commonly uses a non-tumour sample. The report and clinical request explain what was analysed.

Do not infer purpose solely from how the sample was collected. A person may remember giving blood but not the name of the test. Keep the request letter or report heading with the result where possible.

The [NCI inherited-cancer testing fact sheet](https://www.cancer.gov/about-cancer/causes-prevention/genetics/genetic-testing-fact-sheet) explicitly distinguishes inherited-risk testing from tumour testing. It supplies general context, not a personalised eligibility decision or a treatment recommendation.

## Make the distinction visible in your notes

Use separate headings for “tumour assessment” and “inherited-risk assessment” if both are part of your care. Under each, record the test date, specimen, ordering team and the question the report addresses. This is an editorial organisation idea, not an alternative to the medical record.

When preparing a conversation, bring the whole report rather than just a gene name. Ask whether constitutional confirmation has been performed or recommended. If a family discussion is appropriate, ask what information can be shared accurately and what should remain uncertain.

A treatment implication should also stay attached to its cancer context. A biomarker match is not a self-contained instruction to choose a medicine, and a result in one cancer setting cannot automatically be carried into another.

## What you can do with this

The practical next step is small: find the report's purpose and specimen fields before forwarding it. If you cannot locate them, ask the ordering service for clarification. Avoid turning the report into a family-wide statement while those details are missing.

Keeping the two purposes separate makes room for an appropriate connection between them when evidence supports it. It also prevents a useful tumour analysis from being mistaken for a complete answer about inherited risk.

Keep the test purpose in the filename or folder description when organising reports. In a hypothetical household archive, 'tumour testing for treatment discussion' is less ambiguous than 'my DNA results'. That small administrative distinction helps prevent the wrong report being reused for a different question.

For general lifestyle learning, [DomDNA’s educational quiz](https://domdna.com/quiz) does not analyse tumours, estimate inherited cancer risk or select treatment.